Planned Withdrawal of Biologic Therapy in Adults with Takayasu Arteritis in Long-Term Remission After at Least 3 Years of Treatment

What this Trial Is About

Takayasu arteritis is a chronic inflammation of large blood vessels, mainly affecting the aorta and its main branches. This research focuses on evaluating the outcomes of stopping biologic treatments in patients who have maintained long-term remission using these therapies. The study aims to understand how safe it is to discontinue biologic drugs like tumor necrosis factor inhibitors and tocilizumab after at least three years of use in patients with stable disease. Participants will undergo a specific 3-month dose tapering of their biologic medication. If they do not experience a relapse during this tapering phase, they will completely stop the biologic treatment. After stopping, patients will be followed for 12 months to monitor their health. Clinical and laboratory assessments will be done one month after stopping treatment and then every three months. Imaging tests will be done as needed based on clinical evaluations. Throughout the study, researchers will measure how many patients maintain remission 12 months after stopping biologic therapy. They will also track the rate and timing of disease relapse during both the tapering and follow-up periods. Additional analyses will explore factors that might predict relapse and differences related to the type of biologic agent used or other treatments. The total participation includes the tapering period plus a year of follow-up to closely observe patient outcomes.

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission